

ABSTRACT

A problem addressed by the present invention is to provide a new agent for preventing, suppressing symptom progression or recurrence of, and/or treating autoimmune diseases. The inventors of the present invention have diligently studied, and focused on a PD-1/CD3 bispecific antibody as a substance to dissolve such a problem. Furthermore, the inventors have confirmed that the substance could be a formulation which can reduce occurrence of adverse infusion reactions or adverse reaction called cytokine release syndrome. They confirmed that the bispecific antibody has the feature to allow interaction between PD-1 and PD-L1 as its ligand, and found that such a feature contributes enhancement or duration of its effect.